重组人BDNF

总览

脑源性神经营养因子（BDNF）如神经生长因子（NGF）、神经营养因子-3 （NT-3）和神经营养因子-4 （NT-4）一样，是神经营养因子NGF家族的成员，是中枢和周围神经系统中特定神经元亚群分化和存活所必需的(Minichiello & Klein；Minichiello等人)。BDNF以高亲和力结合原肌球蛋白受体激酶B (TrkB)，激活AKT和ERK通路（Mattson等人）。它在基底前脑的海马体、皮质和突触中表达。BDNF作为人胚胎干细胞的存活因子，被镀于饲养细胞或康宁®Matrigel®（Pyle等人）。BDNF调节中枢神经系统成年突触的突触传递和可塑性，并参与适应性神经元反应，包括长期增强、长期抑制、某些形式的短期突触可塑性和神经元兴奋性的稳态调节（Reichardt）。它还通过促进背根神经节细胞、海马和皮质神经元的存活和生长而在神经发生中发挥作用（Binder & Scharfman）。BDNF 与胶质细胞源性神经营养因子（GDNF）及其他补充因子一起，通常用于将人多能干细胞（hPSC）衍生的神经前体细胞分化为神经元（Brafman）。

亚型
细胞因子

细胞类型
神经细胞，PSC衍生，神经干/祖细胞，神经元

种属
人

研究领域
神经科学，干细胞生物学

纯度
≥ 95 %

查看更多显示更少

实验数据

(A) The biological activity of Human Recombinant BDNF was tested by its ability to promote the proliferation of a neuroblastoma cell line stably expressing TrkB (BR6). Cell proliferation was measured using a colorimetric assay method. The EC50 is defined as the effective concentration of the growth factor at which cell proliferation is at 50% of maximum. The EC50 in the above example is 5 ng/mL. For a representative bioactivity plot of C6 cell proliferation, contact us at techsupport@stemcell.com.
(B) 1 μg of Human Recombinant BDNF was resolved with SDS-PAGE under reducing (+) and non-reducing (-) conditions and visualized by Coomassie Blue staining. Human Recombinant BDNF is a homodimer of 13.6 kDa subunits with a predicted molecular mass of 27.3 kDa.

产品说明书及文档

请在《产品说明书》中查找相关支持信息和使用说明，或浏览下方更多实验方案。

Document Type

Product Name

Catalog #

Lot #

Language

Document Type

Product Information Sheet

Product Name

Human Recombinant BDNF

Catalog #

78005.1, 78005, 78005.3, 78005.2

Lot #

All

Language

English

Document Type

Safety Data Sheet

Product Name

Human Recombinant BDNF

Catalog #

78005.1, 78005, 78005.3, 78005.2

Lot #

All

Language

English

应用领域

本产品专为以下研究领域设计，适用于工作流程中的高亮阶段。探索这些工作流程，了解更多我们为各研究领域提供的其他配套产品。

Research Area

Workflow Stages

Workflow Stages for hPSC-Derived Neural Cell Research

Cell Sourcing

Neural Induction

Expansion

Differentiation and Maturation

Characterization

Workflow Stages for Neuronal Research

Tissue Dissociation

Cell Culture

Characterization

相关材料与文献

A Novel Protocol for Directed Differentiation of C9orf72-Associated Human Induced Pluripotent Stem Cells Into Contractile Skeletal Myotubes Swartz EW et al. STEM CELLS Translational Medicine 2016 NOV

Abstract

: Induced pluripotent stem cells (iPSCs) offer an unlimited resource of cells to be used for the study of underlying molecular biology of disease, therapeutic drug screening, and transplant-based regenerative medicine. However, methods for the directed differentiation of skeletal muscle for these purposes remain scarce and incomplete. Here, we present a novel, small molecule-based protocol for the generation of multinucleated skeletal myotubes using eight independent iPSC lines. Through combinatorial inhibition of phosphoinositide 3-kinase (PI3K) and glycogen synthase kinase 3β (GSK3β) with addition of bone morphogenic protein 4 (BMP4) and fibroblast growth factor 2 (FGF2), we report up to 64% conversion of iPSCs into the myogenic program by day 36 as indicated by MYOG+ cell populations. These cells began to exhibit spontaneous contractions as early as 34 days in vitro in the presence of a serum-free medium formulation. We used this protocol to obtain iPSC-derived muscle cells from frontotemporal dementia (FTD) patients harboring C9orf72 hexanucleotide repeat expansions (rGGGGCC), sporadic FTD, and unaffected controls. iPSCs derived from rGGGGCC carriers contained RNA foci but did not vary in differentiation efficiency when compared to unaffected controls nor display mislocalized TDP-43 after as many as 120 days in vitro. This study presents a rapid, efficient, and transgene-free method for generating multinucleated skeletal myotubes from iPSCs and a resource for further modeling the role of skeletal muscle in amyotrophic lateral sclerosis and other motor neuron diseases. SIGNIFICANCE Protocols to produce skeletal myotubes for disease modeling or therapy are scarce and incomplete. The present study efficiently generates functional skeletal myotubes from human induced pluripotent stem cells using a small molecule-based approach. Using this strategy, terminal myogenic induction of up to 64% in 36 days and spontaneously contractile myotubes within 34 days were achieved. Myotubes derived from patients carrying the C9orf72 repeat expansion show no change in differentiation efficiency and normal TDP-43 localization after as many as 120 days in vitro when compared to unaffected controls. This study provides an efficient, novel protocol for the generation of skeletal myotubes from human induced pluripotent stem cells that may serve as a valuable tool in drug discovery and modeling of musculoskeletal and neuromuscular diseases.

View publication

View All Publications